5 news items
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB
14 May 24
-controlled Stage B. In order to enter Stage A and receive efgartigimod SC the diagnosis of CIDP was confirmed by an independent panel of experts. Patients
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA
ZLAB
12 May 24
to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR), progression-free survival (PFS
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
CRDF
JNJ
NTBL
9 May 24
trial replicated, in a second independent and randomized dataset, the bev naïve signal from our earlier Phase
Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Extension In Time To Intracranial Progression For Patients With Brain Metastases From Non-Small Cell Lung Cancer
NVCR
ZLAB
27 Mar 24
progression was calculated according to the cumulative incident function. Patient scans were evaluated by a blinded, independent radiologic review committee
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
NVCR
ZLAB
27 Mar 24
incident function. Patient scans were evaluated by a blinded, independent radiologic review committee. Secondary endpoints include, but are not limited
- Prev
- 1
- Next